• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

    3/23/22 7:30:00 AM ET
    $ATRA
    $NTRA
    $TVTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ATRA alert in real time by email

    Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in July.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005304/en/

    Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022. (Photo: Business Wire)

    Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022. (Photo: Business Wire)

    Currently Senior Vice President, Global Clinical Development and Chief Medical Officer at Merck, Dr. Baynes received his MB, BCh (Bachelor of Medicine and Surgery) from the University of Witwatersrand, where he also received an MMed (specialist registration), and completed a PhD exploring mechanisms of human iron metabolism. After additional clinical training in Johannesburg, and service on the faculty of the Department of Medicine at the University of Witwatersrand Medical School, Dr. Baynes moved to the United States and joined the Division of Hematology in the Department of Medicine at the University of Kansas Medical Center where he served as Professor of Medicine in both hematology and bone marrow transplantation. From 1997 until 2002, Dr. Baynes led the bone marrow transplantation service at the Karmanos Cancer Institute at Wayne State University in Detroit, where he was also a Professor of Medicine (Hematology and Oncology), and the Charles Martin Professor of Cancer Research. Thereafter, Dr. Baynes joined Amgen, Inc., where he became Vice President of Global Development and head of the hematology/oncology development team. He left Amgen in 2012 to become Senior Vice President at Gilead, Inc., and joined Merck in 2013. At Merck he was responsible for the development of the entire clinical portfolio in Merck Research Laboratories, and was the architect of the development strategy for dozens of important new medicines including Keytruda®, a drug that has revolutionized cancer treatment around the world. Dr. Baynes has received innumerable awards for his activities as a physician/scientist, and is currently a board member at Travere, Inc. (NASDAQ:TVTX), Atara, Inc. (NASDAQ:ATRA), and Natera, Inc. (NASDAQ:NTRA).

    "Roy is both a deeply knowledgeable physician and an extraordinary leader, who has assembled top-flight clinical teams in multiple different settings, and has led the development of pioneering new treatments across a broad range of therapeutic areas including cardiovascular medicine, metabolism, infectious disease research, and of course, oncology," said Roger M. Perlmutter, MD, PhD, Chairman and CEO of Eikon Therapeutics. "I consider it a great privilege to have the opportunity to work alongside Roy once again, and to pursue our shared goal of bringing significant new medicines to patients suffering from grievous illness. By any measure, Roy ranks among the most important leaders of clinical development in our industry."

    In his new role, Dr. Baynes will assume responsibility for building the company's clinical research and development team and, eventually, serve as the site leader for a new Eikon Therapeutics facility on the eastern seaboard.

    "I am delighted to have the opportunity to work with Roger again, to join the remarkably talented Eikon Therapeutics team, and to take advantage of their extraordinary skill in applying super-resolution microscopy to the identification of important new medicines," said Dr. Baynes. "I expect that the computational expertise of Eikon's scientists and engineers across machine learning and artificial intelligence will both promote the identification of novel compounds, and the analysis of clinical trial data in powerful new ways that together enable the company to advance new and potentially life-extending medicines."

    About Eikon Therapeutics

    Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and automation with the goal of bringing important new medicines to patients suffering from grievous illness. Scientists at Eikon measure the real-time movement of individual proteins in living cells to develop differentiated therapeutics. Eikon is based in Hayward, California and can be found online via our website or on Twitter or LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005304/en/

    Get the next $ATRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATRA
    $NTRA
    $TVTX

    CompanyDatePrice TargetRatingAnalyst
    Natera Inc.
    $NTRA
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    Natera Inc.
    $NTRA
    1/23/2025$200.00Overweight
    Barclays
    Travere Therapeutics Inc.
    $TVTX
    1/10/2025Overweight
    Cantor Fitzgerald
    Travere Therapeutics Inc.
    $TVTX
    10/21/2024$9.00 → $27.00Equal Weight → Overweight
    Wells Fargo
    Travere Therapeutics Inc.
    $TVTX
    10/16/2024Sector Outperform
    Scotiabank
    Travere Therapeutics Inc.
    $TVTX
    9/9/2024$25.00Neutral → Buy
    Guggenheim
    Natera Inc.
    $NTRA
    6/3/2024$142.00Buy
    Jefferies
    Natera Inc.
    $NTRA
    4/8/2024$117.00Buy
    Craig Hallum
    More analyst ratings

    $ATRA
    $NTRA
    $TVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

      Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

      6/5/23 11:06:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

      Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

      2/23/23 8:05:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

      Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm

      7/11/22 8:00:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATRA
    $NTRA
    $TVTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gallagher Carol Giltner bought $68,214 worth of shares (270,000 units at $0.25), increasing direct ownership by 143% to 459,418 units (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      11/15/23 5:07:08 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dobmeier Eric bought $101,340 worth of shares (446,825 units at $0.23), increasing direct ownership by 384% to 563,325 units (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      11/14/23 6:27:14 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Heiden William K bought $25,330 worth of shares (100,000 units at $0.25), increasing direct ownership by 92% to 209,000 units (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      11/14/23 6:29:04 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    $NTRA
    $TVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Cline Christopher R. converted options into 4,920 shares and sold $37,553 worth of shares (1,784 units at $21.05), increasing direct ownership by 3% to 93,126 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/5/25 9:54:31 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Dube Eric M converted options into 18,924 shares and sold $398,350 worth of shares (18,924 units at $21.05) (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/5/25 9:53:47 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF COMMERCIAL OFFICER Heerma Peter converted options into 4,920 shares and sold $37,280 worth of shares (1,771 units at $21.05), increasing direct ownership by 3% to 128,215 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/5/25 9:53:07 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATRA
    $NTRA
    $TVTX
    Financials

    Live finance-specific insights

    See more
    • Natera Reports First Quarter 2025 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

      5/8/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Travere Therapeutics Reports First Quarter 2025 Financial Results

      Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to full approval for the treatment of IgAN in Europe and the UK Clinical data presented at the National Kidney Foundation Spring Clinical Meetings reinforced FILSPARI's foundational position in IgAN and potential in FSGS Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $322 million Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its first quarter 2025 financial results and provided a corporate update. "As the only fully approve

      5/1/25 4:01:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Natera to Report its First Quarter Results on May 8, 2025

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2025 Financial Results Date: May 8, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-596-4144 (Domestic) 1-646-968-2525 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/454317205 A webcast replay will be available at

      5/1/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $ATRA
    $NTRA
    $TVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Natera Reports First Quarter 2025 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

      5/8/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

      Demonstrates Signatera's ability to predict long-term outcomes in early-stage, high-risk breast cancers Several datasets will be presented, highlighting Natera's leadership in breast cancer MRD Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025. Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap Healthcare Collaborative, will be shared in a mini-oral presentation on May 16, 2025. The report includes data from 712 patients with early-stage, high-ris

      5/8/25 10:30:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Travere Therapeutics to Participate at Upcoming Investor Conferences

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2025 Healthcare Conference Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT Jefferies Global Healthcare Conference Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET Scotiabank Third Annual Healthcare Canadian Investor Day Tuesday, June 17, 2025 Live webcasts of the BofA Securities 2025 Healthcare Conference and Jefferies Global Healthcare Conference presentations will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days followi

      5/7/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATRA
    $NTRA
    $TVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

      SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      11/14/24 6:10:20 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 5:13:38 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

      SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      11/14/24 4:17:31 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    $NTRA
    $TVTX
    SEC Filings

    See more
    • Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Natera, Inc. (0001604821) (Filer)

      5/8/25 4:15:22 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Atara Biotherapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

      5/6/25 4:05:20 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Travere Therapeutics Inc.

      144 - Travere Therapeutics, Inc. (0001438533) (Subject)

      5/5/25 11:32:52 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATRA
    $NTRA
    $TVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on Natera with a new price target

      RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00

      3/13/25 8:17:14 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Natera with a new price target

      Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00

      1/23/25 7:51:22 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Cantor Fitzgerald initiated coverage on Travere Therapeutics

      Cantor Fitzgerald initiated coverage of Travere Therapeutics with a rating of Overweight

      1/10/25 9:14:01 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care